Muscular deficiencies are often associated with central and peripheral neuronal diseases. Charles River offers multiple neuromuscular models, including X-linked muscular dystrophy (MDX) mice for Duchenne muscular dystrophy and experimental allergic encephalomyelitis (EAE) rats and mice for multiple sclerosis. The end-point measurements include basic monitoring and behavioral testing, as well as imaging to assess neuromuscular degeneration and metabolic changes.
The neuromuscular disease service offers phenotyping and efficacy testing of novel therapies. An efficient platform that supports lead selection combines the most relevant imaging modalities, robust sensory-motor behavior testing and biochemical assays—review the supporting data below. You can also read the full story or view a webinar replay.